Emerging as a significant breakthrough in the struggle against obesity, this medication is generating considerable attention . It combines the action of two known GLP-1 receptor agonists, semaglutide , with an additional glucose-dependent incretin component. Preliminary clinical results have indicated substantial weight reduction in patients with o